Tailored Treatments for Premenopausal Women with Endocrine Responsive Breast Cancer. [ 2008 - 2010 ]

Research Grant

Researchers: Prof John Forbes (Principal investigator) ,  A/Pr Jacqueline Chirgwin ,  A/Pr Prudence Francis ,  A/Pr Raymond Snyder ,  Prof Alan Coates
View all 6 related researchers

Brief description For women <50yrs with ER+ breast cancer adjuvant treatment (AT) with chemotherapy (CT), tamoxifen and ovarian function suppression (OFS) are each effective and reduce recurrence. Combining 2 treatments is more effective than 1, but it is unclear if combining 3 provides any extra benefit. 2 trials,SOFT and TEXT, aim to answer this question. SOFT tests the benefit of adding OFS for very young women who remain premenopausal after CT, TEXT is for women who should receive OFS from the start of AT.

Funding Amount $AUD 299,213.61

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant